Team
Science, conviction and experience
Adjuvia's team brings together decades of pharmaceutical development, venture capital, and clinical expertise. United by the belief that the tools to address the root causes of degenerative disease are finally within reach.
Leadership
Laura Hix Glickman, PhD
CO-FOUNDER & CEO
Serial entrepreneur and inventor with over $2.5B in financings, licensing deals, acquisitions, and IPOs.
Named 2020 Top 5 Female Series A Founder in the US (Female Founders Fund) and 2022 CA Top 101 Presidents.
Co-inventor of the synthetic ASX molecule that forms the scientific foundation of our lead asset.
Tim Wilson
CO-FOUNDER & BOARD CHAIRMAN
Company founder with decades of experience building and scaling private and public companies in operating roles as well as a board member/venture capitalist.
Kelly Bryant
CHIEF OPERATING OFFICER
Strategic operations and business leadership across healthcare, biotechnology, and medical technology.
Brings operational discipline and cross-functional expertise to guide our pipeline assets from IND through clinical development.
Gurdyal Kalsi, MD, MFPM
CHIEF MEDICAL OFFICER
Clinical, regulatory, and medical lead for multiple clinical study protocols and development plans with a focus on genetic & rare diseases.
Brings significant medical and business development expertise to guide our pipeline assets' clinical development across multiple disease indications.
Mission
To improve the lives of patients through safe and effective treatments that restore organ function andmodify the course of disease, not just treat its symptoms.
Vision
To lead in medical innovation by advancing transformative therapies that redefine care for patients with complex, life-threatening diseases — united by science, driven by hope.
Advisory board
Pharmaceutical & Legal
Phil Crowley, Esq.
Former Corporate Counsel, Life Sciences, R&D, M&A, Finance & Commercial, FDA Regulations — Johnson & Johnson
Richard Gearhart, Esq.
Former Head, US Patent & Trademark Groups, Novartis; Former General Patent Counsel, Ciba Vision
Geno Germano
Former Group President, Pfizer Global Innovative Pharma (cardiovascular, metabolic, neuroscience, rare disease); Intrexon, Wyeth, J&J, Elucida Oncology, Sage Therapeutics
Frank Sasinowski, M.S., M.P.H., J.D.
Former Deputy Director at FDA; Director at Hyman, Phelps & McNamara, PC — Advisor on 150+ FDA approvals
Scientific
Aaron Esser-Kahn, PhD
Professor of Molecular Engineering, Pritzker School of Molecular Engineering, University of Chicago — Immunoengineering; NFκB inhibitors; inflammatory responses
Peter Havel, PhD, DVM
Professor of Nutrition & Molecular Biosciences, UC Davis School of Veterinary Medicine — Alzheimer's disease and metabolic dysfunction
Clinical
Marni Falk, MD
Executive Director, Mitochondrial Medicine Frontier Program; Distinguished Endowed Chair & Professor, Division of Human Genetics, University of Pennsylvania Perelman School of Medicine; Head of Leigh Syndrome Program